Oncoinvent (ONCIN) investor relations material

Transformative approach to cancer therapy

• Direct alpha therapy platform aims to address high unmet needs in peritoneal metastases, especially ovarian and colorectal cancers.

• RadspherinⓇ delivers alpha-emitting 224Ra via CaCO3 microparticles, targeting and retaining radiation in the peritoneum for localized effect.

• Therapy is administered 1-3 days post-surgery, maximizing local control and minimizing systemic exposure.

• Demonstrates a receptor-independent, non-biological mechanism, effective across multiple cancer types.

• Developed by a team with proven radiopharmaceutical expertise and successful exits.

Clinical development and efficacy

• Phase 1 ovarian cancer trial showed a 10% peritoneal recurrence rate at 24 months, compared to 55-60% in historical controls.

• Colorectal cancer phase 1/2a trial reported a 28% peritoneal recurrence rate at 18 months, versus 50% historically.

• Both studies demonstrated strong safety profiles, with no dose-limiting toxicities and minimal off-target effects.

• Ongoing phase 2 trial in first-line ovarian cancer (N≈110) with FDA Fast Track designation; interim and final results expected through 2028.

• RadspherinⓇ is positioned as a complement to cytoreductive surgery, administered while patients are still hospitalized.

Market opportunity and competitive landscape

• Addressable market includes ~24,000 ovarian cancer patients annually in US and EU5, with potential expansion to other peritoneal and extraperitoneal cancers.

• Limited competition in peritoneal metastases; unique mechanism and logistics offer strategic advantages.

• Radiopharma sector is crowded in other indications, but peritoneal metastases remain largely untapped.

• RadspherinⓇ benefits from simple manufacturing, good raw material supply, and centralized production capabilities.

• Intellectual property protection extends to 2044, covering composition, formulation, use, and combinations.